Discovery of inhibitors that overcome the G1202R ALK Resistance Mutation

The treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib, a small molecule inhibitor of ALK, ROS1, and MET. However, resistance to crizotinib inevitably...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Med Chem
Hlavní autoři: Hatcher, John M., Bahcall, Magda, Choi, Hwan Geun, Gao, Yang, Sim, Taebo, George, Rani, Jänne, Pasi A., Gray, Nathanael S.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4907642/
https://ncbi.nlm.nih.gov/pubmed/26568289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.5b01136
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky